...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of women’s health >Long-term effect of the Women's Health Initiative study on antiosteoporosis medication prescribing.
【24h】

Long-term effect of the Women's Health Initiative study on antiosteoporosis medication prescribing.

机译：妇女健康倡议研究对抗骨质疏松药物处方的长期影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AIM: To describe long-term prescribing patterns of osteoporosis therapy before and after the Women's Health Initiative (WHI) publication. METHODS: We conducted a time-series analysis from 1997 to 2005 using nationally representative data based on office-based physician and hospital ambulatory clinic visits. Bivariate and multivariable analyses were conducted using chi-square tests and logistic regression, respectively, and trends in the prevalence of osteoporosis therapies were evaluated per 6-month (semiannual) intervals. Linear regression and graphic techniques were used to determine statistical differences in the prevalence trends between the two periods. RESULTS: Overall prevalence of therapeutic or preventive osteoporosis therapy was similar between the WHI periods. However, a significant decrease in estrogen therapy and increases in bisphosphonates, calcium/vitamin D were observed in the period after the WHI publication (p < 0.05). Multiple logistic regression analysis showed older age and white race were associated with a higher likelihood of antiosteoporosis medication (AOM) prescription, and Medicaid insurance type was associated with a lower likelihood of an AOM prescription. Excluding calcium/vitamin D, nonestrogen therapy was more likely to be prescribed in the after-WHI period (office-based physician clinic: [adjusted OR, aOR] 2.49 [2.04-4.04]; hospital-based clinic: aOR 2.42 [1.67-7.50]) Nonestrogen therapy was more prevalent in visits made by older women, women of white race, women with contraindicated conditions for estrogen therapy, and women from the Northeast region. CONCLUSIONS: After the WHI publication, the overall prevalence of osteoporosis therapy did not change; however, a shift from estrogen to nonestrogen therapy was observed after the WHI publication. Black women were less likely to receive nonestrogen antiosteoporosis therapy in hospital-based clinics.
机译：目的：描述妇女健康倡议（WHI）出版之前和之后的骨质疏松治疗的长期处方模式。方法：我们根据全国代表性的数据，基于办公室医师和医院门诊就诊时间，对1997年至2005年进行了时间序列分析。分别使用卡方检验和逻辑回归进行了双变量和多变量分析，并且每6个月（半年）评估一次骨质疏松疗法的流行趋势。使用线性回归和图形技术确定两个时期之间流行趋势的统计差异。结果：在WHI期间，治疗性或预防性骨质疏松症治疗的总体患病率相似。然而，在WHI发表后的一段时间内，观察到雌激素治疗的显着减少和双膦酸盐，钙/维生素D的增加（p <0.05）。多元逻辑回归分析显示，年龄较大和白人种族与抗骨质疏松药物（AOM）处方的可能性较高，而医疗补助保险类型与AOM处方的可能性较低。除钙/维生素D外，在WHI之后更可能开具非雌激素疗法（办公室医师诊所：[调整后的OR，aOR] 2.49 [2.04-4.04];医院诊所：aOR 2.42 [1.67- [7.50]）在年龄较大的妇女，白人妇女，有雌激素治疗禁忌症的妇女以及东北地区的妇女中，非雌激素治疗更为普遍。结论：WHI发表后，骨质疏松症治疗的总体患病率没有改变。然而，在WHI发表后，观察到了从雌激素向非雌激素治疗的转变。黑人妇女在医院诊所接受非雌激素抗骨质疏松症治疗的可能性较小。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号